Overcoming Bioanalytical Challenges in Drug Discovery and Biomarker Identification

Gene Ray, Ph.D., Senior Scientific Advisor, KCAS

Dr. Gene Ray is the Senior Scientific Advisor at KCAS for small molecules and Director of Business Development.  Since joining the company in 1990, he has gained expertise in a full range of bioanalytical techniques including LC-MS/MS, GC-MS/MS, ELISA, RIA, protein binding and mass balance investigations. He also serves as technical consultant and board member of a Phase I Investigation Review Board. Gene has experience developing novel methods and has acted as the Principal Bioanalytical Investigator for a vast number of client programs analyzing hundreds of pharmaceutical compounds in blood, urine, and various tissues. Gene has recently presented numerous scientific findings at AAGL, AAPS, ACOG, ACT, ASCPT, ASMS, ASRM, FDA/CDER, SOT, TSRC and WCE. He also is an NIH grant recipient. He previously served as the Assistant Director for numerous analytical chemistry programs for the National Cancer Institute while at Midwest Research Institute.

Lawrence Goodwin, Executive Director Bioanalytical Services, KCAS

Mr. Goodwin is the Executive Director of Bioanalytical R&D and LC-MS/MS Services at KCAS Bioanalytical & Biomarker Services in Shawnee, Kansas. Business development, strategic planning, portfolio expansion, client-based solutions, and driving key scientific objectives for bioanalytical R&D and LC-MS/MS Services are among his primary responsibilities. Mr. Goodwin brings with him the breadth of knowledge to provide scientific and technical leadership across the drug development spectrum including Discovery, Safety Assessment, and Biologics Testing Solutions areas; he has been with KCAS since January 2018.

Lawrence Goodwin has significant drug development aptitude within pharmaceutical and CRO industries. He has lead teams responsible for bioanalytical programs from Discovery through New Drug Application filings. He has more than 25 years’ experience in the Life Sciences industry which includes most recently Eli Lilly and Company and Charles River Laboratories. Leveraging tandem mass spectrometry, Lawrence has made significant contributions in the fields of Bioanalytical, Analytical, Safety Assessment, Biotherapeutics, and Integrated Drug Discovery. He has authored or co-authored more than 35 papers and presentations and provided over 150 internal documents.

Lawrence received his BS in Biological Chemistry from Fontbonne University, St. Louis, Missouri in 1986 and graduated Cum Laude. His continuing education includes the following areas: executive leadership, people and resource management, advanced instrumentation, and GLP training. He has been the recipient of numerous awards both as an individual contributor and as a leader, especially in the areas of tandem mass spectrometry, data management, and process/work-flow efficiency. He is the former chair of the Eli Lilly Mass Spectrometry group and is an active member of American Society for Mass Spectrometry, and a current member of the executive leadership team at KCAS.